Skip to main content

New Drug Approvals - Pt. II - Febuxostat (Uloric/Adenuric)

Second onto market this year is Febuxostat, approved on the 13th of February. Febuxostat is a xanthine oxidase inhibitor used for the treatment of hyperuricemia (gout), and competes against well established agents such as Allopurinol (Allopurinol was approved in 1964 for the treatment of gout). Febuxostat is a small molecule drug (Molecular Weight of 316.4 g.mol-1) is fully Rule-Of-Five compliant, is essentially insoluble in water, and has good oral absorption (>49% bioavailable). Febuxostat plasma half-life of 5 to 8 hours, a volume of distribution of 50L, high plasma protein binding at 99.2% (unsurprising given the lipophilic acid nature of the molecule). Febuxostat is extensively metabolised, both by the UGT system, producing glucoronidated metabolites, and also by a range of complex CYP mediated transformations (metabolites of metabolites....). Some of the CYP mediated metabolites involve hydroxylation of the butyl sidechain, these themselves are pharmacologically active against the target. Roughly half the dose is cleared renally, and the other half in the faeces. Typical daily dosing is 40mg (or ~126┬Ámol), or 80mg if insufficient efficacy is observed. The full prescribing information is here.

The structure (2-[3-cyano- 4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid) contains a nitrile group, and a free carboxylic acid group (which will make the drug negatively charged under physiologic conditions and dominate its physical chemistry). The molecule is quite rigid and comparatively planar (due to the presence of sp2 hybridized atoms adjacent to the core phenyl and thiazole rings). A nitrile is quite unusual in drugs due to its comparative susceptibility to nucleophilic attack, and also metabolic stability - nitriles can be hydrolysed to carboxylic acids.

Febuxostat canonical SMILES: CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O Febuxostat InChI: InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20) Febuxostat InChIKey: BQSJTQLCZDPROO-UHFFFAOYSA-N Febuxostat CAS registry: 144060-53-7 Febuxostat Chemdraw: Febuxostat.cdx

The manufacturer of Febuxostat is Takeda Pharmaceuticals and the product website is


Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site: Please see ChEMBL_34 release notes for full details of all changes in this release: New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the